Narges Sheikhansari: Hello and thank you both for being here today. I’ll start with my first question, please tell us about your team. What are your backgrounds and your founding story?  Pedro Correa de Sampaio [CEO, Neobe Therapeutics]: So, I’ve been working in the tumour microenvironment area for many years, always as an academic. Considering that one ofaaa

Innovator of the Month Interview by Davide Coda and Gian Franco Piredda.   Novigenix is an innovative Swiss molecular diagnostics company specialising in new generation blood tests for early detection of cancer and precision medicine. Founded in 2013, by a group of three scientists from École Polytechnique Fédérale de Lausanne (EPFL), the company is currentlyaaa

More than 14 million people are diagnosed with cancer each year and more than 8 million of those die. Indeed, it is evident that a revolution in terms of cancer treatment is gravely needed. One field which potentially holds great promise is immuno-oncology (IO). IO therapies aim to induce or enhance the immune system toaaa

Grand Challenge is the most ambitious cancer research grant in the world – a series of £20m awards seeking international, multi-disciplinary teams willing to take on the toughest challenges in cancer – providing the freedom to try novel approaches, at scale, in the pursuit of life changing discoveries. In the first round, 9 teams wereaaa

We are delighted to announce our speakers line-up for the Innovation Forum 2016 conference. Follow us to keep up to date as we introduce our eminent speakers. Prof. Chas Bountra is Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. Heaaa